ARGX (argenx SE) Float Percentage Of Total Shares Outstanding: 100.00% (As of Jul. 05, 2026)


ARGX argenx SE ARGX
80 GF Score
Price $939.00
GF Value $1,382.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Float Percentage Of Total Shares Outstanding?

argenx SE ARGX +3.37% 80 Float Percentage Of Total Shares Outstanding is 100.00% as of Jul. 05, 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,382.72 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, argenx SE's float shares is 62.19 Mil. argenx SE's total shares outstanding is 62.19 Mil. argenx SE's float percentage of total shares outstanding is 100.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, argenx SE's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, argenx SE's Institutional Ownership is 46.34%.

ARGX
80GF Score
argenx SE ARGX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

argenx SE's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=62.19/62.19
=100.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 100.00% mean?
argenx SE (ARGX) has a Float Percentage Of Total Shares Outstanding of 100.00% as of Jul. 05, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on argenx SE and its competitors.
Is argenx SE's Float Percentage Of Total Shares Outstanding too high?
argenx SE's current Float Percentage Of Total Shares Outstanding is 100.00%. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
argenx SE's Float Percentage Of Total Shares Outstanding of 100.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on argenx SE and its competitors. argenx SE's current Float Percentage Of Total Shares Outstanding is 100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,382.72, compared to a current price of $939.00 — trading 32.1% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 100.00%. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For argenx SE (ARGX), the current Float Percentage Of Total Shares Outstanding is 100.00% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $939.00 is trading 32.1% below its estimated GF Value™ of $1,382.72. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Float Percentage Of Total Shares Outstanding: 100.00%
  • GF Value™: $1,382.72 vs. price of $939.00 (32.1% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for ARGX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$939.00
Price
$1,382.72
GF Value